South Florida biopharma firm stock rallies following positive clinical trial results


Coral Gables-based drug manufacturer Catalyst Pharmaceuticals is one step closer to launching a drug within the United States’ growing market for treatments of rare diseases.

Catalyst reported Monday that a drug in its pipeline, Firdapse, was found to have positive, “clinically significant” impact on symptoms of Lambert-Eaton myasthenic syndrome, or LEMS, the disease whose side effects Firdapse aims to treat.